317 related articles for article (PubMed ID: 19077395)
21. Combined prostate-specific antigen density and biopsy features to predict "clinically insignificant" prostate cancer.
Loeb S; Roehl KA; Thaxton CS; Catalona WJ
Urology; 2008 Jul; 72(1):143-7. PubMed ID: 18436287
[TBL] [Abstract][Full Text] [Related]
22. Pathological characteristics of prostate cancer detected through prostate specific antigen based screening.
Loeb S; Gonzalez CM; Roehl KA; Han M; Antenor JA; Yap RL; Catalona WJ
J Urol; 2006 Mar; 175(3 Pt 1):902-6. PubMed ID: 16469576
[TBL] [Abstract][Full Text] [Related]
23. Central zone carcinoma of the prostate gland: a distinct tumor type with poor prognostic features.
Cohen RJ; Shannon BA; Phillips M; Moorin RE; Wheeler TM; Garrett KL
J Urol; 2008 May; 179(5):1762-7; discussion 1767. PubMed ID: 18343454
[TBL] [Abstract][Full Text] [Related]
24. PSA-detected (clinical stage T1c or B0) prostate cancer. Pathologically significant tumors.
Oesterling JE; Suman VJ; Zincke H; Bostwick DG
Urol Clin North Am; 1993 Nov; 20(4):687-93. PubMed ID: 7505977
[TBL] [Abstract][Full Text] [Related]
25. Side-specific factors associated with extracapsular extension and seminal vesicular invasion in men undergoing open radical retropubic prostatectomy.
Sankin A; Tareen B; Lepor H
Prostate Cancer Prostatic Dis; 2009; 12(2):204-8. PubMed ID: 19238170
[TBL] [Abstract][Full Text] [Related]
26. Morphological analysis and classification of latent prostate cancer using a 3-dimensional computer algorithm: analysis of tumor volume, grade, tumor doubling time and life expectancy.
Hirano D; Werahera PN; Crawford ED; Lucia MS; DeAntoni EP; Miller GJ
J Urol; 1998 Apr; 159(4):1265-9. PubMed ID: 9507849
[TBL] [Abstract][Full Text] [Related]
27. Is there a relationship between prostate volume and Gleason score?
Mir MC; Planas J; Raventos CX; de Torres IM; Trilla E; Cecchini L; Orsola A; Morote J
BJU Int; 2008 Aug; 102(5):563-5. PubMed ID: 18476971
[TBL] [Abstract][Full Text] [Related]
28. Cancer ablation with regional templates applied to prostatectomy specimens from men who were eligible for focal therapy.
Ward JF; Nakanishi H; Pisters L; Babaian RJ; Troncoso P
BJU Int; 2009 Aug; 104(4):490-7. PubMed ID: 19220260
[TBL] [Abstract][Full Text] [Related]
29. Staging of incidentally detected prostate cancer: role of repeat resection, prostate-specific antigen, needle biopsy, and imaging.
Griebling TL; Williams RD
Semin Urol Oncol; 1996 Aug; 14(3):156-64. PubMed ID: 8865478
[TBL] [Abstract][Full Text] [Related]
30. Can contemporary transrectal prostate biopsy accurately select candidates for hemi-ablative focal therapy of prostate cancer?
Tareen B; Godoy G; Sankin A; Temkin S; Lepor H; Taneja SS
BJU Int; 2009 Jul; 104(2):195-9. PubMed ID: 19191784
[TBL] [Abstract][Full Text] [Related]
31. High-grade foamy gland prostatic adenocarcinoma on biopsy or transurethral resection: a morphologic study of 55 cases.
Zhao J; Epstein JI
Am J Surg Pathol; 2009 Apr; 33(4):583-90. PubMed ID: 19033862
[TBL] [Abstract][Full Text] [Related]
32. The diagnostic and therapeutic window for localized carcinoma of the prostate.
Schmid HP
Ann Urol (Paris); 1994; 28(4):178-83. PubMed ID: 7526772
[TBL] [Abstract][Full Text] [Related]
33. Prostate carcinoma presentation, diagnosis, and staging: an update form the National Cancer Data Base.
Miller DC; Hafez KS; Stewart A; Montie JE; Wei JT
Cancer; 2003 Sep; 98(6):1169-78. PubMed ID: 12973840
[TBL] [Abstract][Full Text] [Related]
34. Characteristics of patients with stage T1b incidental prostate cancer.
Argyropoulos A; Doumas K; Farmakis A; Aristas O; Kontogeorgos G; Lykourinas M
Scand J Urol Nephrol; 2005; 39(4):289-93. PubMed ID: 16118104
[TBL] [Abstract][Full Text] [Related]
35. Impalpable invisible stage T1c prostate cancer: characteristics and clinical relevance in 100 radical prostatectomy specimens--a different view.
Elgamal AA; Van Poppel HP; Van de Voorde WM; Van Dorpe JA; Oyen RH; Baert LV
J Urol; 1997 Jan; 157(1):244-50. PubMed ID: 8976263
[TBL] [Abstract][Full Text] [Related]
36. Is quantitative histologic examination useful to predict nonorgan-confined prostate cancer when saturation biopsy is performed?
Pepe P; Fraggetta F; Galia A; Grasso G; Piccolo S; Aragona F
Urology; 2008 Dec; 72(6):1198-202. PubMed ID: 19041023
[TBL] [Abstract][Full Text] [Related]
37. Clinical characteristics and primary treatment of prostate cancer in Sweden between 1996 and 2005.
Adolfsson J; Garmo H; Varenhorst E; Ahlgren G; Ahlstrand C; Andrén O; Bill-Axelson A; Bratt O; Damber JE; Hellström K; Hellström M; Holmberg E; Holmberg L; Hugosson J; Johansson JE; Petterson B; Törnblom M; Widmark A; Stattin P
Scand J Urol Nephrol; 2007; 41(6):456-77. PubMed ID: 17934985
[TBL] [Abstract][Full Text] [Related]
38. Trends in Gleason score for prostate cancer diagnosed between 1983 and 1993.
Gilliland FD; Gleason DF; Hunt WC; Stone N; Harlan LC; Key CR
J Urol; 2001 Mar; 165(3):846-50. PubMed ID: 11176484
[TBL] [Abstract][Full Text] [Related]
39. How much does Gleason grade of follow-up biopsy differ from that of initial biopsy in untreated, Gleason score 4-7, clinically localized prostate cancer?
Choo R; Danjoux C; Morton G; Szumacher E; Sugar L; Gardner S; Kim M; Choo CM; Klotz L
Prostate; 2007 Nov; 67(15):1614-20. PubMed ID: 17823923
[TBL] [Abstract][Full Text] [Related]
40. Evaluation of a novel precision template-guided biopsy system for detecting prostate cancer.
Megwalu II; Ferguson GG; Wei JT; Mouraviev V; Polascik TJ; Taneja S; Black L; Andriole GL; Kibel AS
BJU Int; 2008 Aug; 102(5):546-50. PubMed ID: 18694408
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
